Engineering of a rough auxotrophic mutant Salmonella Typhimurium for effective delivery
Metrics: PDF 1329 views | HTML 2116 views | ?
Jonathan Lalsiamthara1, Je Hyoung Kim1 and John Hwa Lee1
1College of Veterinary Medicine, Chonbuk National University, Iksan Campus, Iksan 54596, Republic of Korea
John Hwa Lee, email: [email protected]
Keywords: Salmonella Typhimurium; live-attenuated bacterial vector; pre-existing immunity; heterologous antigen delivery
Received: September 05, 2017 Accepted: April 05, 2018 Published: May 22, 2018
Live Salmonella vaccine vectors offer a remarkable platform for delivering immunogens and therapeutic molecules by mimicking natural intracellular infections; however, pre-existing anti-vector immunity can impede effective deployment. Measures to alleviate pre-existing immunity include the use of heterologous vectors, development of highly attenuated strain enabling greater payload, removal of major immunoreactive components from the vector, and/or augmentation of delivered antigens via increased presentation in antigen presenting cells. Here we report a Salmonella Typhimurium (ST) vector-JOL1800 that embodies these requisite properties. JOL1800 is a highly attenuated, auxotrophic, and O-antigen deficient rough-mutant strain. Heterologous bacterial and viral antigens were expressed and delivered using JOL1800 in mice, irrespective of the inoculation route successful inductions of the mucosal and systemic humoral responses were observed. Compared to smooth LPS vector delivery, we observed an increased fraction of delivered-antigen presenting dendritic cells and a higher frequency of delivered-antigen displayed per macrophage. Upon post-priming with JOL1800 delivery, efficacy of the delivery was minimally affected as indicated by insignificant decrease in colonization, humoral and cellular responses. Our results show that the generated vector is capable of remote antigen delivery, manifests higher antigen presentation, is Differentiating Infected from Vaccinated Animals (DIVA) capable, evades normal pre-existing immunity, and can be deployed for effective delivery.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.